{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:00:44Z","timestamp":1792620044409,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000885","name":"Children's Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002086","name":"Fanconi Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013187","name":"Randy Shaver Cancer Research & Community Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymthe.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:54:08Z","timestamp":1773273248000},"page":"3456-3471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficient multiplex non-viral engineering and expansion of polyclonal \u03b3\u03b4 CAR-T cells for immunotherapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Jacob","family":"Bridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-1742","authenticated-orcid":false,"given":"Matthew J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibekananda","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Wenthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell G.","family":"Kluesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lage","family":"von Dissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Skeate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branden S.","family":"Moriarity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-8747","authenticated-orcid":false,"given":"Beau R.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.03.007_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/334395a0","article-title":"T-cell antigen receptor genes and T-cell recognition","volume":"334","author":"Davis","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.007_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0923-2494(96)89648-9","article-title":"Stimulation of gamma delta T cells by phosphoantigens","volume":"147","author":"Fourni\u00e9","year":"1996","journal-title":"Res. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1126\/science.8146660","article-title":"Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands","volume":"264","author":"Constant","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.03.007_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human gamma delta T cells","volume":"375","author":"Tanaka","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.007_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.03.007_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2015.00015","article-title":"Five Layers of Receptor Signaling in \u03b3\u03b4 T-Cell Differentiation and Activation","volume":"6","author":"Ribeiro","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nri2604","article-title":"Oncogenic stress sensed by the immune system: role of natural killer cell receptors","volume":"9","author":"Raulet","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.03.007_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41590-024-01892-z","article-title":"V\u03b39V\u03b42 T cells recognize butyrophilin 2A1 and 3A1 heteromers","volume":"25","author":"Fulford","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/14737140.5.6.973","article-title":"Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma","volume":"5","author":"Viey","year":"2005","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ymthe.2026.03.007_bib11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","article-title":"Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition","volume":"66","author":"Wrobel","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.imbio.2007.10.006","article-title":"Innate immune functions of human gammadelta T cells","volume":"213","author":"Beetz","year":"2008","journal-title":"Immunobiology"},{"key":"10.1016\/j.ymthe.2026.03.007_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cellimm.2014.11.001","article-title":"Chicago 2014--30 years of \u03b3\u03b4 T cells","volume":"296","author":"Bonneville","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/156800910790980188","article-title":"Gammadelta T cell modulation in anticancer treatment","volume":"10","author":"Caccamo","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ymthe.2026.03.007_bib15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1097\/01.ju.0000154355.45816.0b","article-title":"Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro","volume":"173","author":"Liu","year":"2005","journal-title":"J. Urol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-007-0279-2","article-title":"Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity","volume":"56","author":"Mattarollo","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.03.007_bib17","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/eji.200838354","article-title":"A subset of IL-10-producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury","volume":"38","author":"Rhodes","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1084\/jem.191.6.937","article-title":"Self-recognition of CD1 by gamma\/delta T cells: implications for innate immunity","volume":"191","author":"Spada","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.03.007_bib19","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25821","article-title":"Combining conventional chemotherapy and \u03b3\u03b4 T cell-based immunotherapy to target cancer-initiating cells","volume":"2","author":"Todaro","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.03.007_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573920","article-title":"High Abundance of Intratumoral \u03b3\u03b4 T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1347742","article-title":"Distinctive features of tumor-infiltrating \u03b3\u03b4 T lymphocytes in human colorectal cancer","volume":"6","author":"Meraviglia","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.03.007_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1353858","article-title":"Tumor-infiltrating \u03b3\u03b4T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.03.007_bib23","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.007_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib25","article-title":"A close look at current \u03b3\u03b4 T-cell immunotherapy","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/imr.12920","article-title":"Beyond CAR T cells: Engineered V\u03b39V\u03b42 T cells to fight solid tumors","volume":"298","author":"Rafia","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.03.007_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1360237","article-title":"Advancements in \u03b3\u03b4T cell engineering: paving the way for enhanced cancer immunotherapy","volume":"15","author":"Yuan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.007_bib29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical applications of gamma delta T cells with multivalent immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib30","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","article-title":"Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies","volume":"20","author":"Deniger","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.007_bib31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4049\/jimmunol.151.3.1214","article-title":"Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma\/V2DJC delta-encoded T cell receptors","volume":"151","author":"Davodeau","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.immunol.14.1.511","article-title":"Recognition by gamma\/delta T cells","volume":"14","author":"Chien","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","article-title":"[gamma] [delta] cells: a right time and a right place for a conserved third way of protection","volume":"18","author":"Hayday","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","article-title":"Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri797","article-title":"Gammadelta T cells: functional plasticity and heterogeneity","volume":"2","author":"Carding","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ni.2240","article-title":"Body-barrier surveillance by epidermal \u03b3\u03b4 TCRs","volume":"13","author":"Chodaczek","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-065X.2006.00473.x","article-title":"Curriculum vitae of intestinal intraepithelial T cells: their developmental and behavioral characteristics","volume":"215","author":"Ishikawa","year":"2007","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.03.007_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","article-title":"The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"1","author":"Nussbaumer","year":"2019","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.imlet.2018.02.002","article-title":"Human V\u03b43+ \u03b3\u03b4 T cells induce maturation and IgM secretion by B cells","volume":"196","author":"Petrasca","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2026.03.007_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cei\/uxac032","article-title":"Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by V\u03b42+ T cells compared with the aminobisphosphonate drug zoledronic acid","volume":"208","author":"Fenn","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2057012","article-title":"Dissecting the cellular components of ex vivo \u03b3\u03b4 T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials","volume":"11","author":"Jonus","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.03.007_bib42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.03.007_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2362.2009.02171.x","article-title":"Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells","volume":"39","author":"Petrini","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.007_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cmi.2011.16","article-title":"Anti-\u03b3\u03b4 TCR antibody-expanded \u03b3\u03b4 T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies","volume":"9","author":"Zhou","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1336870","article-title":"Isolation and expansion of pure and functional \u03b3\u03b4 T cells","volume":"15","author":"Verkerk","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib46","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion\/Differentiation and Preclinical Proof of Concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.007_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib48","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00262-022-03260-y","article-title":"CAR \u03b3\u03b4 T cells for cancer immunotherapy. Is the field more yellow than green?","volume":"72","author":"Ganapathy","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.03.007_bib50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","article-title":"Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity","volume":"126","author":"Rischer","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib51","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.ymthe.2017.03.002","article-title":"Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor","volume":"25","author":"Fisher","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.007_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005400","article-title":"Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia","volume":"10","author":"S\u00e1nchez Mart\u00ednez","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.007_bib53","first-page":"682","article-title":"Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade","volume":"3","author":"Palmer","year":"2022","journal-title":"Med (N. Y.)"},{"key":"10.1016\/j.ymthe.2026.03.007_bib54","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.03.007_bib55","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","article-title":"Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors","volume":"10","author":"Webber","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.03.007_bib56","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI121491","article-title":"T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy","volume":"129","author":"Yamamoto","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.007_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.007_bib58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fimmu.2019.00218","article-title":"Genetic modification strategies to enhance CAR T cell persistence for patients with solid tumors","volume":"10","author":"DeRenzo","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.03.007_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-61779-352-3_11","article-title":"Generation of high-expressing cells by methotrexate amplification of destabilized dihydrofolate reductase selection marker","volume":"801","author":"Ng","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.007_bib62","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fimmu.2020.00326","article-title":"Emerging approaches for regulation and control of CAR T cells: A mini review","volume":"11","author":"Brandt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells","volume":"128","author":"Riddell","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymthe.2026.03.007_bib64","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-024-03763-7","article-title":"Ex vivo expansion and activation of V\u03b39V\u03b42 T cells by CELMoDs in combination with zoledronic acid","volume":"119","author":"Inoue","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of effector\/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites","volume":"198","author":"Dieli","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.03.007_bib66","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","article-title":"Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies","volume":"32","author":"Skeate","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.007_bib67","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.03.007_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2020.03.283","article-title":"Vector copy number quality control testing for CAR T-cells: critical validation parameters","volume":"22","author":"Chen","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.03.007_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0008-6363(99)00267-9","article-title":"T cells expressing the gamma delta T cell receptor induce apoptosis in cardiac myocytes","volume":"45","author":"Huber","year":"2000","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ymthe.2026.03.007_bib70","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.intimp.2011.01.001","article-title":"IFN-\u03b3 enhances HOS and U2OS cell lines susceptibility to \u03b3\u03b4 T cell-mediated killing through the Fas\/Fas ligand pathway","volume":"11","author":"Li","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib71","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","article-title":"CAR-engineered lymphocyte persistence is governed by a FAS ligand\/FAS auto-regulatory circuit","volume":"10","author":"Yi","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.007_bib87","article-title":"Installation of dominant-negative mutations in FAS and TGF\u03b2R2 via base editing in primary T cells","volume":"33","author":"Wick","year":"2025","journal-title":"Mol. Ther. Onc."},{"key":"10.1016\/j.ymthe.2026.03.007_bib72","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u03b3c Family of Cytokines: Basic Biology to Therapeutic Ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.03.007_bib73","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1084\/jem.20150304","article-title":"Cish actively silences TCR signaling in CD8 + T cells to maintain tumor tolerance","volume":"212","author":"Palmer","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.03.007_bib74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","article-title":"Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels","volume":"28","author":"Lv","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2026.03.007_bib75","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1038\/s41598-018-23549-2","article-title":"The Cish SH2 domain is essential for PLC-\u03b31 regulation in TCR stimulated CD8+ T cells","volume":"8","author":"Guittard","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.03.007_bib76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13046-023-02770-6","article-title":"CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma","volume":"42","author":"Nakazawa","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.007_bib77","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/JLB.2MA0620-074R","article-title":"Drug target validation in primary human natural killer cells using CRISPR RNP","volume":"108","author":"Rautela","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.007_bib79","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41551-023-01157-4","article-title":"Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair","volume":"8","author":"Webber","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.03.007_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051305","article-title":"\u03b3\u03b4 T Cells: The Ideal Tool for Cancer Immunotherapy","volume":"9","author":"Yazdanifar","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.03.007_bib81","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nsmb.1920","article-title":"The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations","volume":"17","author":"Wang","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.03.007_bib82","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V89.3.902","article-title":"Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis","volume":"89","author":"Bettinardi","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.03.007_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gks596","article-title":"Primer3--new capabilities and interfaces","volume":"40","author":"Untergasser","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.03.007_bib84","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/crispr.2018.0014","article-title":"EditR: A Method to Quantify Base Editing from Sanger Sequencing","volume":"1","author":"Kluesner","year":"2018","journal-title":"CRISPR J."},{"key":"10.1016\/j.ymthe.2026.03.007_bib85","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3465","article-title":"Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol","volume":"9","author":"Crowe","year":"2019","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.ymthe.2026.03.007_bib86","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/cac2.12074","article-title":"T-cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications","volume":"40","author":"Li","year":"2020","journal-title":"Cancer Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:19:18Z","timestamp":1788178758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525001626001929"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.007","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.03.611042","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient multiplex non-viral engineering and expansion of polyclonal \u03b3\u03b4 CAR-T cells for immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}